The UK parallel import licensing scheme lets a medicine authorized in a European Economic Area (EEA) Member State be marketed in the UK, as long as the imported product has no therapeutic difference from the cross-referenced UK product.
The MR-DC product list in the section “Make a TaD variation” has been updated.
Read more online